Antianginal Drugs

The book explores the significant advancements in therapeutic options for coronary pathology, particularly focusing on antianginal medications. It discusses the reasons behind the surge in these treatments, including the unsatisfactory nature of existing medications and the large patient population suffering from coronary heart disease, which presents lucrative opportunities for pharmaceutical companies. Additionally, it highlights the rapid progress in understanding angina's physiopathology, leading to innovative pharmacological developments and new substances tailored for cardiac pain management.